Siponimod Structural Formula (Baf312 01)
Mayzent Tablet, Film Coated
Product Images NDC 0078-1014
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Mayzent (NDC 0078-1014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 Time To Confirmed Disability Progression Based On Edss (study 1) (Baf312 02)
This appears to be a graph or chart comparing results of a study between a drug called "Mayzent" and a placebo. The study involved 1,099 patients taking Mayzent and 546 taking a placebo. The graph shows the percentage of patients with confirmed EDSS progression over a period of time (12, 24, and 30 months). The study found that Mayzent showed a 21% reduction in relative risk compared to placebo, with a p-value of 0.013 and 95% confidence interval of 0.65 to 0.95.*
Figure 2 Time To Confirmed Disability Progression Based On Edss (study 1), Subgroup Analysis (Baf312 03)
Novartis Logo (Baf312 04)
Principal Display Panel Ndc 0078-0986-15 Rx Only Mayzent® (siponimod) Tablets 2 mg 30 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 05)
Principal Display Panel Ndc 0078-0979-50 Rx Only Mayzent® (siponimod) Tablets 0.25 mg 28 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 06)
Baf312 07
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
